プロテアソーム阻害薬の世界市場予測・分析:種類別・地域別

◆英語タイトル:Proteasome Inhibitors Market by Product and Geography - Global Forecast 2019-2023
◆商品コード:IRTNTR31647
◆発行会社(リサーチ会社):Technavio
◆発行日:2019年7月20日
◆ページ数:136
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:アジア、ヨーロッパ、北米、その他
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD2,500 ⇒換算¥275,000見積依頼/購入/質問フォーム
Five User(5名様閲覧用)USD3,000 ⇒換算¥330,000見積依頼/購入/質問フォーム
Enterprise License(同一法人内共有可)USD4,000 ⇒換算¥440,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はTechnavio社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
Technavio社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

Technavio社の本調査レポートでは、プロテアソーム阻害薬の世界市場について調べ、プロテアソーム阻害薬の市場状況、市場規模、市場予測、市場環境、顧客状況、市場動向、関連企業情報などをまとめました。また、プロテアソーム阻害薬の市場規模をセグメンテーション別(種類別(ベルケード、キプロリス、ニンラロ、その他の製品)、)と地域別(アジア、ヨーロッパ、北米、その他)に分けて算出しました。Technavio社はプロテアソーム阻害薬の世界市場規模が2019-2023期間中に年平均8%成長すると予測しています。
・サマリー
・レポートの範囲
・プロテアソーム阻害薬の市場状況
・プロテアソーム阻害薬の市場規模
・プロテアソーム阻害薬の市場予測
・プロテアソーム阻害薬の世界環境:ファイブフォース分析
・市場セグメンテーション:種類別(ベルケード、キプロリス、ニンラロ、その他の製品)
・プロテアソーム阻害薬の顧客状況
・主要地域別市場規模:アジア、ヨーロッパ、北米、その他
・意思決定フレームワーク
・市場動向・成長要因・課題
・関連企業状況・企業分析
 ...
【レポートの概要】

Global Proteasome Inhibitors Market: About this market

Proteasome inhibitors are used for the treatment of multiple myeloma. Technavio’s proteasome inhibitors market analysis considers sales from VELCADE, KYPROLIS, NINLARO, and other products segments. Our analysis also considers the sales of proteasome inhibitors in Asia, Europe, North America, and ROW. In 2018, the VELCADE segment held the highest market share, which is expected to remain prevalent over the forecast period. The drug is the first proteasome inhibitor to receive approvals from the FDA and EMA. Moreover, the drug is the most effective in treating multiple myeloma. These factors will significantly help the VELCADE segment in maintaining its leading market position. Also, our global proteasome inhibitors report has observed market growth factors such as the huge unmet need, strong adoption rate, and growing incidence of myeloma. However, the threat from biologics, strong adverse effects, and slow regulatory approval may hamper the growth of the proteasome inhibitors industry over the forecast period.

Global Proteasome Inhibitors Market: Overview

Huge unmet need

There is a significant unmet treatment need for myeloma and a few solid tumor indications. Vendors are leveraging this situation and are focusing on developing therapeutics for the same. The market also has only a few approved therapies. As a result, there is significant scope for vendors to expand into the market. Therefore, the huge unmet need and the rising incidence of cancer will propel the growth of the global proteasome inhibitors market over the forecast period. The market is expected to record a CAGR of about 8% during the forecast period.

Expanded application

Apart from treating myeloma and solid tumors, proteasome inhibitor drugs are also being used to cure non-oncology conditions. For instance, ACU-D1 is a novel proteasome inhibitor that is proven to treat rosacea. The drug is in its second phase of clinical studies. There is ongoing research on expanding applications of proteasome inhibitor drugs to treat other conditions. This factor will have a positive impact on the overall market growth.

For the detailed list of factors that will drive the global proteasome inhibitors market during the forecast period 2019-2023, click here.

Competitive Landscape

With the presence of a few major players, the global proteasome inhibitors market is concentrated. Technavio’s robust vendor analysis is designed to help clients in improving their market positions, and in line with this, this report provides a detailed analysis of several leading proteasome inhibitors producers, which include Allergan Plc, Amgen Inc., Celgene Corp., Johnson & Johnson Services Inc., and Takeda Pharmaceutical Co. Ltd.

Also, the proteasome inhibitors market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage on all forthcoming growth opportunities.

【レポートの目次】

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

2.1 Preface

2.2 Preface

2.3 Currency conversion rates for US$

PART 03: MARKET LANDSCAPE

Market ecosystem

Market characteristics

Market segmentation analysis

PART 04: MARKET SIZING

Market definition

Market sizing 2018

Market size and forecast 2018-2023

PART 05: FIVE FORCES ANALYSIS

Bargaining power of buyers

Bargaining power of suppliers

Threat of new entrants

Threat of substitutes

Threat of rivalry

Market condition

PART 06: PIPELINE ANALYSIS

PART 07: MARKET SEGMENTATION BY PRODUCT

Market segmentation by product

Comparison by product

VELCADE – Market size and forecast 2018-2023

KYPROLIS – Market size and forecast 2018-2023

NINLARO – Market size and forecast 2018-2023

Other products – Market size and forecast 2018-2023

Market opportunity by product

PART 08: CUSTOMER LANDSCAPE

PART 09: GEOGRAPHIC LANDSCAPE

Geographic segmentation

Geographic comparison

North America – Market size and forecast 2018-2023

Europe – Market size and forecast 2018-2023

Asia – Market size and forecast 2018-2023

ROW – Market size and forecast 2018-2023

Key leading countries

Market opportunity

PART 10: DECISION FRAMEWORK

PART 11: DRIVERS AND CHALLENGES

Market drivers

Market challenges

PART 12: MARKET TRENDS

Expanded application

Strategic alliances

Special drug designations

PART 13: VENDOR LANDSCAPE

Overview

Landscape disruption

Competitive scenario

PART 14: VENDOR ANALYSIS

Vendors covered

Vendor classification

Market positioning of vendors

Allergan Plc

Amgen Inc.

Celgene Corp.

Johnson & Johnson Services Inc.

Takeda Pharmaceutical Co. Ltd.

PART 15: APPENDIX

Research methodology

List of abbreviations

Definition of market positioning of vendors

PART 16: EXPLORE TECHNAVIO

Exhibit 01: Global pharmaceuticals market

Exhibit 02: Segments of global pharmaceuticals market

Exhibit 03: Market characteristics

Exhibit 04: Market segments

Exhibit 05: Market definition – Inclusions and exclusions checklist

Exhibit 06: Market size 2018

Exhibit 07: Global market: Size and forecast 2018-2023 ($ millions)

Exhibit 08: Global market: Year-over-year growth 2019-2023 (%)

Exhibit 09: Five forces analysis 2018

Exhibit 10: Five forces analysis 2023

Exhibit 11: Bargaining power of buyers

Exhibit 12: Bargaining power of suppliers

Exhibit 13: Threat of new entrants

Exhibit 14: Threat of substitutes

Exhibit 15: Threat of rivalry

Exhibit 16: Market condition – Five forces 2018

Exhibit 17: Global proteasome inhibitors market pipeline: Overview

Exhibit 18: Global proteasome inhibitors market pipeline: Snapshot

Exhibit 19: Product – Market share 2018-2023 (%)

Exhibit 20: Comparison by product

Exhibit 21: VELCADE – Market size and forecast 2018-2023 ($ millions)

Exhibit 22: VELCADE – Year-over-year growth 2019-2023 (%)

Exhibit 23: KYPROLIS – Market size and forecast 2018-2023 ($ millions)

Exhibit 24: KYPROLIS – Year-over-year growth 2019-2023 (%)

Exhibit 25: NINLARO – Market size and forecast 2018-2023 ($ millions)

Exhibit 26: NINLARO – Year-over-year growth 2019-2023 (%)

Exhibit 27: Other products – Market size and forecast 2018-2023 ($ millions)

Exhibit 28: Other products – Year-over-year growth 2019-2023 (%)

Exhibit 29: Market opportunity by product

Exhibit 30: Customer landscape

Exhibit 31: Market share by geography 2018-2023 (%)

Exhibit 32: Geographic comparison

Exhibit 33: North America – Market size and forecast 2018-2023 ($ millions)

Exhibit 34: North America – Year-over-year growth 2019-2023 (%)

Exhibit 35: Top 3 countries in North America

Exhibit 36: Europe – Market size and forecast 2018-2023 ($ millions)

Exhibit 37: Europe – Year-over-year growth 2019-2023 (%)

Exhibit 38: Top 3 countries in Europe

Exhibit 39: Asia – Market size and forecast 2018-2023 ($ millions)

Exhibit 40: Asia – Year-over-year growth 2019-2023 (%)

Exhibit 41: Top 3 countries in Asia

Exhibit 42: ROW – Market size and forecast 2018-2023 ($ millions)

Exhibit 43: ROW – Year-over-year growth 2019-2023 (%)

Exhibit 44: Top 3 countries in ROW

Exhibit 45: Key leading countries

Exhibit 46: Market opportunity

Exhibit 47: Impact of drivers and challenges

Exhibit 48: Vendor landscape

Exhibit 49: Landscape disruption

Exhibit 50: Vendors covered

Exhibit 51: Vendor classification

Exhibit 52: Market positioning of vendors

Exhibit 53: Allergan Plc – Vendor overview

Exhibit 54: Allergan Plc – Product segments

Exhibit 55: Allergan Plc – Organizational developments

Exhibit 56: Allergan Plc – Geographic focus

Exhibit 57: Allergan Plc – Segment focus

Exhibit 58: Allergan Plc – Key offerings

Exhibit 59: Allergan Plc – Key customers

Exhibit 60: Amgen Inc. – Vendor overview

Exhibit 61: Amgen Inc. – Business segments

Exhibit 62: Amgen Inc. – Organizational developments

Exhibit 63: Amgen Inc. – Geographic focus

Exhibit 64: Amgen Inc. – Key offerings

Exhibit 65: Amgen Inc. – Key customers

Exhibit 66: Celgene Corp. – Vendor overview

Exhibit 67: Celgene Corp. – Business segments

Exhibit 68: Celgene Corp. – Organizational developments

Exhibit 69: Celgene Corp. – Geographic focus

Exhibit 70: Celgene Corp. – Key offerings

Exhibit 71: Celgene Corp. – Key customers

Exhibit 72: Johnson & Johnson Services Inc. – Vendor overview

Exhibit 73: Johnson & Johnson Services Inc. – Business segments

Exhibit 74: Johnson & Johnson Services Inc. – Organizational developments

Exhibit 75: Johnson & Johnson Services Inc. – Geographic focus

Exhibit 76: Johnson & Johnson Services Inc. – Segment focus

Exhibit 77: Johnson & Johnson Services Inc. – Key offerings

Exhibit 78: Johnson & Johnson Services Inc. – Key customers

Exhibit 79: Takeda Pharmaceutical Co. Ltd. – Vendor overview

Exhibit 80: Takeda Pharmaceutical Co. Ltd. – Business segments

Exhibit 81: Takeda Pharmaceutical Co. Ltd. – Organizational developments

Exhibit 82: Takeda Pharmaceutical Co. Ltd. – Geographic focus

Exhibit 83: Takeda Pharmaceutical Co. Ltd. – Key offerings

Exhibit 84: Takeda Pharmaceutical Co. Ltd. – Key customers

Exhibit 85: Validation techniques employed for market sizing

Exhibit 86: List of abbreviations

Exhibit 87: Definition of market positioning of vendors



【掲載企業】

Allergan Plc, Amgen Inc., Celgene Corp., Johnson & Johnson Services Inc., and Takeda Pharmaceutical Co. Ltd.

【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[プロテアソーム阻害薬の世界市場予測・分析:種類別・地域別]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆